ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

ClinicalTrials.gov ID: NCT06833008

Public ClinicalTrials.gov record NCT06833008. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours

Study identification

NCT ID
NCT06833008
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Ipsen
Industry
Enrollment
85 participants

Conditions and interventions

Interventions

  • IPN01195 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 13, 2025
Primary completion
Oct 2, 2028
Completion
Oct 2, 2028
Last update posted
Apr 29, 2026

2025 – 2028

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
START Mid-West Grand Rapids Michigan 49546 Recruiting
Sarah Cannon Research Institute (SCRI) - Nashville Nashville Tennessee 37203 Recruiting
Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas Dallas Texas 75230 Recruiting
START Mountan Region West Valley City Utah 84119 Recruiting
Virginia Cancer Specialist- Fairfax Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06833008, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06833008 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →